Quick Shot #2 Answer
Answer: Vedolizumab, infliximab or ozanimod
Per current FDA guidelines, tofacitinib can only be used in a patient who has failed an anti-tumor necrosis factor agent. This is not first line therapy, though effective. In the head-to-head VARSITY trial, vedolizumab was superior to adalimumab for moderate to severe UC. Therefore, AGA guidelines recommend vedolizumab over adalimumab for first line therapy in a biologic naïve patient. Infliximab, vedolizumab and ozanimod are all appropriate therapies in this scenario.